Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • REV1–DHX36 Coordination Enables Replication Across G-Quadrup

    2026-07-17

    REV1–DHX36 Coordination Enables Replication Across G-Quadruplex DNA

    Study Background and Research Question

    Non-canonical DNA structures—particularly G-quadruplexes (G4 DNA)—pose significant obstacles to faithful genome replication. Guanine-rich regions capable of forming these four-stranded secondary structures are abundant in the human genome and are recognized barriers to replication fork progression, particularly under conditions of replication stress or DNA damage. Yet, the precise mechanisms by which human cells coordinate bypass and tolerance of G4 DNA during replication remain incompletely understood. The reference study by Ketkar et al. (Nucleic Acids Research, 2026) addresses a central knowledge gap: How do specialized replication factors, notably the translesion synthesis polymerase REV1 and the G4-resolving helicase DHX36, mechanistically interact to preserve genome integrity at G4-prone loci?

    Key Innovation from the Reference Study

    The study’s core innovation lies in its discovery of a direct, domain-specific interaction between human REV1 and DHX36, which together establish a two-tiered mechanism for G4 replication tolerance. Through precise mapping of the protein-protein interface, the authors identify a newly defined region at the C-terminus of DHX36 that binds the C-terminal domain (CTD) of REV1. This interaction is functionally critical: it coordinates helicase-mediated G4 unwinding with suppression of single-stranded DNA (ssDNA) gap formation, ultimately promoting faithful replication across G4 structures (Ketkar et al., 2026).

    Methods and Experimental Design Insights

    Ketkar et al. combined genetic, biochemical, and cell biological approaches in both human cell lines and in vitro systems. The key methodologies included:

    • Gene knockdown and complementation: REV1 and/or DHX36 were depleted using siRNA or CRISPR-based strategies, with functional rescue via domain-mutant or wild-type constructs.
    • Replication fork progression assays: DNA fiber analysis quantified how loss of REV1 or DHX36 altered fork dynamics, particularly under G4-stabilizing conditions (e.g., pyridostatin treatment).
    • Protein interaction mapping: Pull-down and co-immunoprecipitation experiments defined the direct binding regions between REV1 and DHX36.
    • Single-stranded DNA gap detection: Immunofluorescence and molecular assays measured ssDNA gap formation at G4 sites.
    • Assessment of DNA damage signaling: Phosphorylation status of ATM/ATR pathway components was monitored as a readout for replication stress.
    The experimental design allowed the group to dissect both the physical interactions and the functional consequences of REV1–DHX36 coordination during G4 replication.


    Core Findings and Why They Matter

    The study’s findings advance our understanding of genome maintenance at several levels:

    • REV1 is essential for coordinated G4 bypass: Cells lacking REV1 displayed compromised fork elongation, which was rerouted to a PrimPol-driven pathway. This rerouting resulted in defective suppression of ssDNA gaps, especially after exposure to G4-stabilizing agents like pyridostatin.
    • Leading versus lagging strand asymmetry: Mutagenic replication at G4 motifs was differentially affected in leading versus lagging strand contexts. REV1 loss more severely impacted leading strand G4 replication, yet lagging strand mutagenesis was uniquely sensitive to chemical G4 stabilization.
    • ATM/ATR pathway activation: The absence of REV1 led to increased nuclear G4 signals and an amplified DNA damage response, specifically via ATM/ATR signaling. This aligns with the concept that persistent G4 structures can act as endogenous DNA damage inducers (see discussion of ATM signaling and DNA damage response).
    • REV1–DHX36 interaction is direct and domain-specific: The C-terminal domain of REV1 binds a unique region in DHX36, physically scaffolding helicase activity at G4 sites. When prolonged G4 stabilization disrupted this interaction, DHX36 accumulated distal from both REV1 and the core replication machinery, leading to increased genome instability.
    • Two-tiered mechanism for G4 tolerance: The study proposes that REV1’s scaffolding function not only facilitates helicase-dependent unwinding but also suppresses the formation of ssDNA gaps, which are otherwise prone to breakage and mutagenesis.
    Overall, these results establish mechanistic clarity for how the human replisome adapts to G4 obstacles, with direct relevance to genome stability and disease etiology, particularly in cancer where G4-rich regions and DNA damage response pathways are frequently dysregulated.


    Comparison with Existing Internal Articles

    Several internal resources contextualize and extend the findings of Ketkar et al. For example, the analysis in "REV1-DHX36 Interaction Promotes Replication Across G-Quadruplex DNA" further explores REV1’s scaffolding function, echoing the reference study’s emphasis on single-stranded DNA gap suppression and genome stability. Additionally, resources dedicated to ATM kinase inhibitors, such as "AZD1390: Practical Guide to ATM Kinase Inhibitor Use in DNA Repair Studies", discuss how perturbing the ATM signaling axis with agents like AZD1390 can be leveraged to experimentally probe DNA double-strand break repair and radiosensitization—directly relevant to the increased ATM/ATR signaling observed upon G4 replication stress in the reference study. There is a clear methodological bridge: understanding how REV1/DHX36 loss amplifies ATM signaling can inform the use of selective ATM kinase inhibitors for dissecting DNA damage response resilience in cancer models.

    Limitations and Transferability

    While comprehensive, the study is primarily based on cultured cell systems, and the direct in vivo relevance of the REV1–DHX36 interaction at endogenous G4 loci in human tissues warrants further exploration. The domain mapping and protein interaction findings, though robust, may not fully capture the dynamic chromatin context of higher-order eukaryotic genomes. Moreover, the interplay between REV1/DHX36 and other G4-resolving factors, or their role in complex tumor microenvironments, remains to be elucidated. Transferability to clinical models, such as glioblastoma or lung cancer, will require validation under physiologically relevant conditions and in the context of DNA damage response modulation.

    Protocol Parameters

    • Pyridostatin treatment: Used at concentrations (typically 5–20 μM) to stabilize G4 DNA and induce replication stress in cell culture assays; titrate to optimize for cell line and endpoint assay.
    • siRNA/CRISPR-mediated knockdown: REV1 and DHX36 depletion validated by immunoblotting; rescue with wild-type or interaction-deficient mutants to confirm domain-specific effects.
    • DNA fiber assay: Label ongoing replication with CldU/IdU analogs; analyze fork progression and stalling in G4-stabilized versus control conditions.
    • ATM/ATR pathway analysis: Phosphorylation-specific antibodies (e.g., p-ATM Ser1981) used to monitor signaling pathway activation post-G4 stabilization or inhibitor treatment.
    • ssDNA gap detection: Employ BrdU immunofluorescence under non-denaturing conditions or molecular combing techniques.
    • G4 structure detection: Use G4-specific antibodies or chemical probes for immunofluorescence microscopy.

    Research Support Resources

    For researchers investigating the mechanisms of DNA replication stress, damage tolerance, or radiosensitization in cancer models, selective ATM kinase inhibitors represent a valuable tool to manipulate the DNA damage response pathway. AZD1390 (SKU B8328) is a potent, selective ATM inhibitor with demonstrated efficacy in cellular and in vivo models of glioma and lung cancer. Its application can be particularly informative in studies seeking to dissect ATM signaling following G4-induced replication stress or in radiosensitization workflows. Detailed protocols, solubility considerations, and best practices for AZD1390 are outlined in internal guides such as "AZD1390: ATM Kinase Inhibitor Workflows for Cancer Research". As always, solution stability and assay context should be carefully considered to maximize reproducibility and data integrity.